NEW YORK (GenomeWeb) – Foundation Medicine said this week that it quickly resolved an issue regarding reporting of tumor mutational burden (TMB) by its FoundationOne CDx test that had surfaced in October.

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect.